ACTRN12612000052831招募中未知
Can early response measurement by FDG PET/CT in patients with metastatic colorectal cancer receiving third-line therapy with cetuximab predict the progression-free survival and overall survival?
Chang Gung Memorial Hospital0 个研究点目标入组 30 人开始时间: 2012年1月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. at least one measurable lesion as defined by RECIST criteria.
- •2. received both the irinotecan-based and oxaliplatin-based regimens.
- •3. must have tumor specimen determined to have wild-type K-ras.
排除标准
- •1. History of another primary malignancy less than 3 years
- •2. Prior treatment with cetuximab or panitumumab
研究者
相似试验
已完成
不适用
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.lung cancerNL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50
招募中
不适用
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 TherapyMetastatic MelanomaNCT03888950Centre Hospitalier Universitaire de Nice20
招募中
2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)s lymphomaHodgkin'JPRN-UMIN000019093Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)50
进行中（未招募）
2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)JPRN-jRCTs041180174Koga Yuhki50
招募中
不适用
The predictive value of FDG-PET-CT early during (chemo-)radiotherapy for local control of advanced stage head and neck cancerNL-OMON32415Vrije Universiteit Medisch Centrum20